EnteroMedics Therapy Fails to Meet Weight-Loss Study Goal

EnteroMedics Inc. said its implanted nerve-blocking therapy failed to help patients lose as much weight as intended in a key obesity study. The company’s shares lost almost two-thirds of their value in extended trading.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.